Nova Scotia Business Leaders MedMira and Tri-Star Industries Enter Strategic Marketing Partnership

    HALIFAX, March 24 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, and Tri-Star Industries (Tri-Star), a leading Canadian manufacturer
and exporter of ground ambulances, announced today that they are forming a
strategic marketing partnership.
    Under the agreement Tri-Star and MedMira will market and sell co-branded
rapid diagnostics, extending both companies' market reach and exposure while
establishing new revenue streams. Together, MedMira and Tri-Star will tap
opportunities in Latin America, the Caribbean, and the Middle East where
Tri-Star has developed in-depth market knowledge and customer bases.
    "We are excited to add a Nova Scotia company like Tri-Star to our growing
base of strategic global partners. Besides the fact that we are both Nova
Scotia companies, there are many other synergies between Tri-Star and MedMira
that we believe will make this a successful partnership," said Hermes Chan,
CEO, MedMira Inc. "Tri-Star brings a wealth of knowledge and experience in
navigating the complexities of Latin American, Caribbean, and Middle Eastern
markets where demand exists for quality diagnostics."
    The MedMira/Tri-Star partnership enables each to bring critical success
factors together in order to deliver positive, revenue generating results.
Under the terms of the agreement, MedMira will manufacture its complete line
of rapid diagnostics, which includes HIV, hepatitis and multiple tests built
on the Company's patented and award-winning rapid flow-through technology
platform, and Tri-Star will obtain regulatory approvals, promote, and sell the
co-branded tests through their existing and newly established sales channels
in Latin America, the Caribbean and the Middle East.
    "Partnering with MedMira enables us to expand our product offering to
existing customers in the healthcare sector, while creating new revenue
streams for both companies," said Keith Condon, CEO Tri-Star Industries. "The
powerful combination of MedMira's quality diagnostics with our first-hand
experience in these markets will enable the streamlined delivery of critical
healthcare solutions to regions where they can do the most good and are most
needed."

    About Tri-Star Industries

    Tri-Star, founded in 1973, specializes in the custom design & manufacture
of ambulances and specialty vehicles to the highest quality & safety
standards. Internationally renowned, the company is a winner of nine Export
Achievement Awards. Its products have reached customers in 44 countries.
Tri-Star markets in Canada, and overseas its market focus is Europe, Middle
East, Caribbean, and Central and South America. Tri-Star is Ford QVM approved,
CMVSS registered, and ISO 9001:2000 certified. The company, which operates
under a Total Quality Management System, is located in Yarmouth, Nova Scotia,
where it has a modern 60,000 square feet factory. For more information, visit
Tri-Star's web site at www.tri-star.ca.

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E

For further information: MedMira: Andrea Young, Corporate
Communications, (902) 450-1588, ayoung@medmira.com